L (P = .003), and the absence of leukemic cell CD10 expression ( P < .001). In a stratified statistical analysis adjusted for age and treatment protocol, MLL gene rearrangement was correlated with an inferior treatment outcome ( P = .028). The 4-year event-free survival estimate (?SE) was 10% k 6.5% for cases with a rearranged MLL gene and 64% C 19.2% for other cases. When infants were excluded from the analysis, MLL rearrangement was still significantly associated with a poor outcome (P = .02), and remained so with the exclusion of t(4;llJ-positive cases (P= .05). Thus, regardless of presenting age, MLL gene rearrangement identifies a high-risk subgroup of patients who are not likely to be cured with conventional treatment. of MLL rearrangements in ALL of infants (70% to 80%) that may account for the dismal prognosis in this subgroup."."," More recently, we attributed the relatively favorable prognosis of ALL with deletions or inversions of the 1 lq23 region to the lack of MLL rearrangement." Whether rearrangements of the MLL gene has prognostic importance in children over 1 year of age or in those with 1 lq23 translocations other than the t(4; 1 1 ) is unknown. Therefore, we studied a large cohort of childhood ALL patients with various 1 lq23 abnormalities to address these issues.
MATERIALS AND METHODS

Putients.
From September 1984 to September 1994,715 consecutive children with newly diagnosed ALL were admitted to St Jude Children's Research Hospital and enrolled in one ofthree successive clinical trials, designated Total Therapy studies XI-XIII,'h.'7 at St Jude Children's Research Hospital. Although testing different therapeutic strategies, these protocols uniformly relied on a similar multidrug induction regimen and intensification therapy. The diagnosis of ALL was based on morphologic criteria of the French-AmericanBritish (FAB) Cooperative Group," and confirmed by immunologic testing. Leukemic cells were successfully karyotyped in 669 cases, S3 (8%) of which had abnormalities of chromosome 1 lq23. Immunophenotyping studies. Surface antigens were detected on leukemic cells by standard indirect immunofluorescence assays with monoclonal antibodies to lymphoid-and myeloid-associated antigens. Blast cells were also tested for surface (slg) and cytoplasmic (clg) immunoglobulin as previously described." Depending on reactivity patterns, cells were classified as T (CD7' plus CD2', CD3 ' .
or CDS'), B (slg'), pre-B (clg'). transitional pre-B (clgp'. algp'. slgC, slgx-), or early pre-B (clg-, slg", HLA-DR', CD19', CD10').2' Southern blot analysis. Genomic DNA was extracted from leukemic blasts obtained from patients at diagnosis. Aliquots (5 to IO pg) of high-molecular-weight DNA were digested with BamH1, HindIII, and Sac I restriction endonucleases, separated by electrophoresis in 0.8% agarose gels, and blotted onto nylon membranes using a standard Southern method. All blots were hybridized with a "P-labeled probe, termed MLL (Oncor, Gaithersburg, MD), derived from a 0.74-kb BumHI cDNA fragment of the MLL gene." The probe detects the common breakpoints of MLL between exons 5 through 1 I with BamHI digests, and breaks centromeric to exon 5 and telomeric to exon 11 with Hind111 and Sac I digests (Fig I) . Membranes containing BamHI and Hind111 restricted DNA of cases demonstrating germline MLL bands with the cDNA MLL probe were stripped, and then sequentially examined with MLL genomic probes 98.40, 4.2E. and PS/4.'r.22.Z3 When used in parallel studies, these four probes detect breaks between exons 2 and I8 with DNA restricted with BamHI or Hind111 (Fig I) . The 4.2E probe required 300 pg/mL total human placental DNA (Sigma Chemical CO, St Louis, MO) in the hybridization solution to block repetitive sequences. All blots included restricted DNA from a cervical carcinoma cell line that has two normal MLL genes. All blots also included DNA from the RS4; 11 cell line that contains one normal MLL gene and one MLL gene split by the t(4; 11) translocation." Hybridized membranes were exposed to Kodak XAR-5 film (Eastman Kodak, Rochester, NY) at -70°C for 5 to 7 days.
Blood
Statistical analysis. Because of the limited number of patient samples, analyses were adjusted only for age and treatment that largely corrects for other presenting risk features. Event-free survival curves were constructed by the Kaplan-Meier method and were compared by the stratified log-rank test. Values ( P ) of .05 or less for survival were considered significant. Differences in the distribution of presenting features [age, sex, race, leukocyte count, central nervous system leukemia, CDIO, CD15, DNA index, mediastinal mass, and the t(4; 11) translocation] between cases with or without MLL rearrangements were tested by the two-sided Fisher exact test. For comparisons of presenting features, we adjusted the target significance value (.05) to compensate for the problem of multiple signiticance testing. This was done by dividing the target value of .05 by the number of comparisons performed (n = 10 in these analyses), so that a P value of at least ,005 was required to declare statistical significance.
RESULTS
Of the 45 cases studied, 30 (67%) had an 1 lq23 translocation, 13 (29%) had a del(1 l)(q23), and 2 (4%) an inv( 1 l)(pl3q23). The modal chromosome number was 46 in all but eight cases-4 with 47 chromosomes, 2 with 45, and 1 each with 48 and 55 ( Table 1 ). The distribution of balanced translocations favored the t(4; I l)(q21 ;q23) and the t(l l ; 19)(q23;p13) [including a t(2; 19; 1 l)(q33;p13:q23) variant], each present in eight cases, followed by the t(9; ll)(p21;q23) in two additional cases. The remaining five cases had other llq23 translocations, including a t(4; 1 l)(q31;q23) in an infant with pre-B leukemia (Table  1 , patient 12). In addition to a del(1 l)(q23) or der(l1) t( I l;?)(q23;?), leukemic cells of patients 29, 3 I , and 40 also contained a t(9;22)(q34;ql l), but these children surprisingly remain free of disease at 33+, 43+ and 54+ months, respectively.
A rearranged MLL gene was demonstrated in 21 of the 45 cases using the cDNA probe and BarnHI digests. Two additional cases (patients 2 and 3) were detected with HindIII and Suc I digests. To exclude possible MLL breaks in the (Tables 1 and 2 ). Rearrangement of MLL was detected in 20 of 23 cases with a balanced translocation, including all 18 cases with the common t(4; I 1 ), t( 1 I; 19) or t(9; 1 I), and 2 of 5 cases (patients 9, 12, 22,23, and 26) with other balanced 1 lq23 translocations. In Includes patient 4 with a t(2;19;1l)(q33;p13;q23). t Includes patient 12 with a t(4;11)(q31;q23) and 7 patients with unbalanced translocations. The "V" in t(ll;V)(q23;V) indicates variable or unknown translocation partners. addition, 3 of 7 cases with an unbalanced I lq23 translocation involved the MLL gene (Fig 2) . None of the 15 cases with either del( I l)(q23) or inv( 1 I)(pl3q23) demonstrated an abnormal MLL gene.
The presence of an MLL rearrangement was significantly associated with age less than 1 year ( P < .001), leukocyte count >50 X IOy/L ( P = .003), and lack of CD10 expression ( P < .001) ( Table 3) . Cases with rearranged MLL also had a higher frequency of initial CNS leukemia and CD15 expression than did other cases. When infant cases were excluded from the analysis, MLL rearrangements were correlated with lack of CD10 and aberrant CD15 expression ( P = .005 and P = .001, respectively), and tended to have higher leukocyte counts ( P = .03) ( Table 4) . With further elimination of the t(4; 1 l)-positive cases from the group older than I year, none of the presenting features were significantly associated with MLL rearrangement. The Kaplan-Meier estimate of event-free survival (+SE) for all patients at 4 years of follow-up was 10% 5 6.5% for patients with a rearranged MLL gene and 6 4 % + 19.2% for those without this abnormality (Fig 3) . The difference in outcome was significant by the stratified log-rank test after adjustment for age (< I v > 1 year) and treatment ( P = .028).
When the analysis was restricted to patients > I year of age, MLL rearrangement still correlated with an inferior treatment outcome ( P = .02, Fig 4) . Even when only cases over 1 year of age with no t(4; 1 1) were analyzed, MLL rearrangement remained an adverse prognostic feature ( P = .05). Results of this latter analysis are not likely to be confounded by other presenting risk factors, because these factors did not differ significantly between children greater than 1 year of age with a rearranged MLL gene but no t(4; 1 1) and patients greater than 1 year of age and normal MLL genes. Of the 7 patients with an 1 lq23 translocation that did not involve MLL, only patients 9 and 34 had an adverse event; the other Table 1 . Blots were hybridized with a cDNA probe that recognizes sequences between exons 5 and l 1 of the MLL gene. Arrowheads identify the 8.5-kb band of germline MLL. Lanes labeled "RS" show one germline band and t w o additional bands respresenting one normal MLL gene and one splithearranged MLL gene, respectively. Cases 6, 12, 7, and 17 (lanes labeled accordingly) had der(ll)t(7;117)17;pl4 -q23;7), t(4;11)(q3l;q231, t(9;ll)(p21;q23) and t(ll;19)(q23;p13), respectively, and show a germline band and one or t w o additional rearranged bands. All other cases had translocations of 1 lq23 and show only germline bands. Values less than .005 are considered significant (see comment in Materials and Methods for correction of significance values in multiple comparisons). Not included in the table are comparisons for the t(4;ll) translocation, DNA index, and mediastinal mass. Of these three features, only the t(4;ll) was significantly associated with MLL gene rearrangement.
ment was found in all cases with the common t(4; 1 I), t( 1 1 ; 19) or t(9; 1 l ) translocations; however, not all cases with other 1 lq23 translocations involved this gene, especially patients over I year of age. Cases with deletions or inversions of 1 lq23 also did not have MLL rearrangements. It is unlikely that rearrangements of MLL were missed in this study, because the multiple probes used should have detected all breaks between exons 2 and 18. Indeed, the reported breakpoints of MLL in acute leukemias have oc- curred exclusively between exons 4 and 15.R"0~'"i5~22~25 Several other genes, including RCK and PLZF, can also be involved in 1 lq23 translocations in cases of myeloid leukemias and lymphomas,'-' but they were not evaluated in the present analysis. In contrast to other molecular studies of pediatric leukemias with chromosome llq23 abnormalities, 7 of our 12 patients with unbalanced or uncommon translocations of 1 lq23 had no detectable breaks of the MLL gene. In two previous studies, all of 16 leukemia patients with translocations or aberrations of 1 lq23 other than t(4; 1 l), t(6; 1 l), t(9; 1 l), and t( 1 l: 19), demonstrated rearrangements of MLL.9.22 However, only 2 of these 16 patients had ALL. This suggests that in acute leukemias with chromosome 1 lq23 abnormalities, breaks in loci other than MLL may be more common in ALL than in AML. This may be especially true for older children with ALL, because 6 of our 7 patients with unbalanced or uncommon translocations of l lq23 and no rearrangement of MLL were over age 1 year.
In agreement with previous molecular s t~d i e s , '~.~~. '~ we show that infants with ALL and rearrangement of MLL have an extremely poor prognosis. Furthermore, the poor outcome in infants with MLL gene rearrangements is irrespective of the type of cytogenetic abnormality. Of the 14 infants with MLL rearrangements, 4 of 5 with t(4; 11) and 7 of 9 with other I lq23 translocations failed treatment. These findings are in agreement with a larger molecular study of infant ALL," but contrasts with a smaller cytogenetic study.26 In the latter study, the investigators suggested that the specific t(4; 11) translocation, and not other llq23 translocations or abnormalities, was associated with the poor prognosis of infants. Because this latter study did not include molecular studies for rearrangements of the MLL gene, it is possible that some of the non-t(4; 11) cases did not involve the MLL gene and hence account for a better treatment outcome. More importantly, the adverse prognostic impact of an MLL rearrangement in infant ALL appears to extend to older children.
The poor outcome relationship in older children was seen even when the analysis excluded cases with the t(4; 11) translocation. Thus, the poor prognosis of older children with ALL involving the MLL gene is further evidence of this gene's adverse influence on clinical outcome, irrespective of the 1 lq23 chromosome partner.
The investigators of a previous study of childhood ALL with the t(4; 11) suggest that age has a significant prognostic impact on outcome for patients over I year of age.27.28 This study, which did not include molecular studies for MLL gene rearrangements, found that 3 of 8 (38%) patients with ages from 1 to 9 years failed therapy as compared to 7 of 8 (88%) patients 10 years of age or older. In the present study 60% or more of patients in both age groups had a poor clinical outcome. An explanation for the different outcome in our patients in not readily evident, but may be due to differences in therapy or to the small number of patients investigated. Although unlikely, it is also possible that the translocations in some of the patients in the t(4; l 1) study did not involve the MLL gene. The t(4; 1 l)(q21;q23) is thought to be invariably associated with rearrangement of the MLL but a single case of t(4; I I ) without a detectable rearrangement of MLL was described in a large molecular study of infant ALL." These unexplained differences clearly indicate the need for a larger, prospective cytogenetic and molecular investigation to determine the prognostic impact of MLL gene rearrangements in patients with ALL who are 1 to 9 years old.
The results of this investigation provide a compelling reason to test for MLL rearrangements in all newly diagnosed cases of ALL entered onto treatment protocols. Cytogenetic studies may fail to detect llq23 translocations, even in inabnormalities, especially children older than 1 year, may not involve the MLL gene." Further, this report underscores the increasingly important role of molecular studies in establishing prognostic categories of childhood ALL and the need to fants.lZ.i5. 30 A substantial proportion of cases with llq23 For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From devise treatments specifically directed to the molecular events underlying leukemogenesis. This study and others have clearly shown that infants and older children with ALL and a rearranged MLL gene, irrespective of cytogenetic findings, have a very poor prognosis and should be considered for innovative therapies, including bone marrow transplant. Additional investigations into the prognostic importance of MLL gene rearrangements in ALL in children between I and 9 years of age are required before making more definitive therapeutic recommendations for this patient group.
